Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias

Leukemia and Lymphoma

Volumn 25, Issue 3-4, 1997, Pages 247-256

  Perentesis, John P ^a,b   Bendel, Anne E ^a   Shao, Yu ^a   Warman, Berta ^a   Davies, Stella M ^a   Yang, Chang H ^a   Chandan Langlie, Mridula ^a   Waddick, Kevin G ^a   Uckun, Fatih M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Diphtheria toxin; Drug resistance; Myeloid leukemia; Recombinant fusion toxin

Indexed keywords

CARRIER PROTEIN; CYTOKINE RECEPTOR; DIPHTHERIA TOXIN; GLYCOPROTEIN P; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MULTIDRUG RESISTANCE PROTEIN; PROTEIN; PROTEIN BCL 2; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CELL KILLING; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MEMBRANE TRANSPORT; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STEM CELL; TUMOR SUPPRESSOR GENE;

EID: 0030976350     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709114164     Document Type: Article

References (60)

1. Gottesman, M. M. (1993). How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award lecture. Cancer Research, 53, 747-754.
2. Rohatiner, A. and Lister, T. A. (1996). Acute Myelogenous Leukemia in Adults. In Leukemia, 6th edn., edited by E. S. Henderson, T. A. Lister and M. F. Greaves, pp. 479-508. Philadelphia: W. B. Saunders.
3. Chan, H. S., DeBoer, G., Thorner, P. S., Haddad, G., Gallie, B. L. and Ling, V. (1994). Multidrug resistance: Clinical opportunities in diagnosis and circumvention, Hematology and Oncology Clinics of North America, 8, 383-410.
4. Arceci, R. (1993). Clinical significance of P-glycoprotein in multidrug resistant malignancies, Blood, 81, 2215-2222.
5. Licht, T., Pastan, I., Gottesman, M. and Herrmann, F. (1994). P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells, Annals of Hematology, 69, 159-171.
6. Endicott, J. A. and Ling, V. (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance, Annual Reviews of Biochemistry, 58, 137-171.
7. Marsh, W., Sicheri, D. and Center, M. S. (1986). Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug, Cancer Research, 46, 4053-4057.
8. Bhalla, K., Hindenburg, A., Taub, R. N. and Grant, S. (1985). Isolation and characterization of an anthracycline-resistant human leukemic cell line, Cancer Research, 45, 3657-3662.
9. Cole, S. P., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V. and Deeley, R. G. (1992). Overexpression of a transporter gene in a multi-drug resistant human lung cancer cell line, Science, 258, 1650-1654.
10. Scheffer, G. L., Wijngaard, P. L. J., Flens, M. J., Izquierdo, M. A., Slovak, M. L., Pinedo, H. M., Meijer, C. J. L., Clevers, H. C. and Scheper, R. J. (1995). The drug resistance-related protein LRP is the human major vault protein, Nature Medicine, 1, 578-582.
11. Campos, L., Guyotat, D., Archimbaud, E., Calmard, O. P., Tsuruo, T., Troncy, J., Treille, D. and Fiere, D. (1992). Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis, Blood, 79, 473-476.
12. Musto, P., Melillo, L., Lombards, G., Matera, R., Di Giorgio, G. and Carotenuto, M. (1991). High risk of early resistant relapse for leukemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission, British Journal of Haematology, 77, 50-53.
13. Pirker, R., Wallner, J., Geissler, K., Linkesch, W., Haas, O. A., Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P., Havelec, L., Ludwig, H. and Lechner, K. (1991). MDR1 gene expression and treatment outcome in acute myeloid leukemia, Journal of the National Cancer Institute, 83, 708-712.
14. Marie, J.-P., Zittoun, R. and Sikic, B. I. (1991) Multidrug resistance (mdrl) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity, Blood, 78, 586-592.
15. Sato, H., Gottesman, M. M., Goldstein, L. J., Pastan, I., Block, A. M., Sandberg, A. A. and Preisler, H. D. (1990) Expression of the multidrug resistance gene in myeloid leukemias, Leukemia Research, 14, 11-21.
16. Sato, H., Preisler, H., Day, R., Raza, A., Larson, R., Browman, G., Goldberg, J., Vogler, R., Grunwald, H., Gottlieb, A., Bennet, J., Gottesman, M. and Pastan, I. (1990). MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukemia, British Journal of Hematology, 75, 340-345.
17. Schneider, E., Cowan, K. H., Bader, H., Toomey, S., Schwartz, G. N., Karp, J. E., Burke, P. J. and Kaufmann, S. H. (1995). Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia, Blood, 85, 186-93.
18. Slapak, C. A., Mizunuma, N. and Kufe, D. W. (1994). Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells, Blood, 84, 3113-3321.
19. Fisher, D. E. (1994). Apoptosis in cancer therapy: Crossing the threshold, Cell, 78, 539-542.
20. Thompson, C. B. (1995). Apoptosis in the pathogenesis and treatment of disease, Science, 267, 1456-1462.
21. Sachs, L. and Lotem, J. (1993). Control of programmed cell death in normal and leukemic cells New implications for therapy, Blood, 82, 15-21.
22. Dive, C. and Hickman, J. A. (1991). Drug-target interactions: Only the first step in the commitment to a programmed cell death? British Journal of Cancer, 64, 192-196.
23. Kerr, J. F. R., Winterford, C. M. and Harmon, B. V. (1994). Apoptosis: Its significance in cancer and cancer therapy, Cancer, 73, 2013-2026.
24. Perentesis, J. P., Miller, S. P. and Bodley, J. W. (1992). Protein toxin inhibitors of protein synthesis, Biofactors, 3, 173-184.
25. Yamaizumi, J., Mekada, E., Uchida, T. and Okada, Y. (1978). One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell, Cell, 15, 245-250.
26. Williams, D. P., Parker, K., Bacha, P., Bishai, W., Borowski, M., Genbauffe, F., Strom, T. B. and Murphy, J. R. (1987). Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein,. Protein Engineering, 1, 493-98.
27. Jean, L. F. and Murphy, J. R. (1991). Diphtheria toxin receptor-binding domain substitution with interleukin 6. Genetic construction and interleukin 6 receptor-specific action of a diphtheria toxin-related interleukin 6 fusion protein. Protein Engineering, 4, 989-94.
28. Lakkis, F., Steele, A., Pacheco-Silva, A., Rubin-Kelley, V., Strom, T. B. and Murphy, J. R. (1991). Interleukin 4 receptor targeted cytotoxicity: Genetic construction and in vivo immunosuppresive activity of a diphtheria toxin-related murine interleukin 4 tusion protein, European Journal of Immunology, 21, 2253-58.
29. Shaw, J. P., Akiyoshi, D. E., Arrigo, D. A., Rhoad, A. E., Sullivan, B., Thomas, J., Genbauffe, F. G., Bacha, P. and Nichols, J. C. (1991). Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins, Journal of Biological Chemistry, 266, 21118-24.
30. LeMaistre, C. F., Meneghetti, C., Rosenblum, M., Reuben, J., Parker, K., Shaw, J., Deisseroth, A., Woodworth, T. and Parkinson, D. R. (1992). Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor, Blood, 79, 2547-54.
31. LeMaistre, C. F., Craig, F. E., Meneghetti, C., McMullin, B., Parker, K., Reuben, J., Boldt, D. H., Rosenblum, M. and Woodworth, T. (1993). Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematologic cancers, Cancer Research, 53, 3930-34.
32. Perentesis, J. P., Genbauffe, F. S., Veldman, S. A., Galeotti, C. L., Livingston, D. M. Bodley, J. W. and Murphy, J. R. (1988). Expression of diphtheria toxin fragment A and hormone-toxin fusion proteins in toxin-resistant yeast mutants, Proceedings of the National Academy of Sciences USA, 85, 8386-90.
33. Lubbert, M. and Mertelsmann, R. (1993). In: Leukemia: Advances, Research and Treatment (eds: Freireich EJ & Kantarjian H) pp. 171.
34. Young, D. C., Demetri, G. D., Ernst, T. J., Cannistra, S. A. and Griffin, J. D. (1988). In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells, Experimental Hematology, 16, 378-382.
35. Young, D. C. and Griffin, J. D. (1986). Autocrine secretion of GMCSF in acute myeloblastic leukemia, Blood, 68, 1178-1181.
36. Young, D. C., Wagner, K. and Griffin, J. D. (1987). Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia, Journal of Clinical Investigation, 79, 100-106.
37. Rogers, S. Y., Bradbury, D., Kozlowski, R. and Russell, N. H. (1994). Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Experimental Hematology, 22, 593-98.
38. Cannistra, S. A., Groshek, P. and Griffin, J. D. (1989). Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myelogenous leukemia, Leukemia, 3, 328-334.
39. Ganser, A., Völkers, B., Greher, J., Ottmann, O. G., Walther, F., Becher, R., Bergmann, L., Schulz, G. and Hoelzer, D. (1989). Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes-a phase I/II trial, Blood, 73, 31-37.
40. Herrmann, F., Lindemann, A., Klein, H., Lubbert, M., Schulz, G. and Mertelsmann, R. (1989). Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia, 31, 335-338.
41. Hiddemann, W., Koenigsmann, M., Zuhlsdorf, M., Wormann, B., Boeckmann, A., Freire, E. A., Innig, G., Maschmeyer, G., Ludwig, W. D. et al. (1991). Recombinant human granulocyte-macrophage colony stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse, Blood, 78, 1190-1197.
42. Gasson, J. C. (1991). Molecular physiology of granulocyte-macrophage colony-stimulating factor, Blood, 77, 1131-1145.
43. Berdel, W. E., Danhauser-Riedl, S., Steinhauser, G. and Winton, E. F. (1989). Various human hematopoietic growth factors (interleukin-3, GMCSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells, Blood, 74, 1446-1447.
44. Baldwin, G. C., Gasson, J. C., Kaufman, S. E., Quan, S. G., Williams, R. E., Avalos, B. R., Gazdar, A. F., Golde, D. W. and DiPersio, J. F. (1989). Nonhematopoietic tumor cells express functional GMCSF receptors, Blood, 7, 1033-1037.
45. Avalos, B. R., Gasson, J., Hedvat, C., Gasson, J. C., Hedvat, C., Quan, S. G., Baldwin, G. C., Weisbart, R. H., Williams, R. E., Golde, D. W. and DiPersio, J. F. (1990). Human granulocyte colony-stimulating factor: biological activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines, Blood, 75, 851-857.
46. Collins, S. J. (1987). The HL-60 promyelocytic leukemia cell line Proliferation, differentiation, and cellular oncogen expression, Blood, 70, 1233-44.
47. Stong, R. C., Korsmeyer, S. J., Parkin, J. L., Arthur, D. C. and Kersey, J. H. (1985). Human acute leukemia cell line with the t(4,11) chromosomal rearrangement exhibits B lineage and monocytic characteristics, Blood, 65, 21-31.
48. Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick, K. G., Ahlgren, L. T., Chelstrom, L. M., Burkhardt, A., Bolen, J. and Myers, D. E. (1995). Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases, Science, 267, 886-891.
49. Uckun, F. M., Mitchell, J. B., Obuz, V., Park, C. H., Waddick, K., Friedman, N., Oubaha, L., Min, W. S. and Song, C. W. (1991). Radiation sensitivity of human B-lineage lymphoid precursor cells, International Journal of Radiation Oncology, Biology and Physics, 21, 1553-1560.
50. McGrath, T. and Center, M. S. (1988). Mechanisms of multidrug resistance in HL-60 cells' Evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug, Cancer Research, 48, 3959-3963.
51. Krishnamachary, N. and Center, M. S. (1993). The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein, Cancer Research, 53, 3658-3661.
52. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival. Application to proliferation and cytotoxicity assays, Journal of Immunological Methods, 65, 55-63.
53. Uckun, F. M., Ramakrishnan, S. and Houston, L. L. (1985). Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell -specific immunotoxin con- taining pokeweed antiviral protein, Cancer Research, 45, 69-75.
54. Uckun, F. M., Ramakrishnan, S. and Houston. L. L. (1985). Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow, Journal of Immunology, 134, 2010-2016.
55. Myers, D. E., Uckun, F. M., Ball, E. D. and Vallera, D. A. (1988). Immunotoxins for ex vivo marrow purging in autologous bone marrow transplantation for acute nonlymphocytic leukemia, Transplantation, 46, 240-245.
56. Uckun, F. M., Gajl-Peczalska, K. J., Kersey, J. H., Houston, L. L. and Vallera, D. A. (1986). Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing poke-weed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia, Journal of Experimental Medicine, 163, 347-368.
57. Uckun, F. M., Stong, R. C., Youle, R. J. and Vallera, D. A. (1985). Combined ex vivo treatment with immunotoxins and mafosfamid: A novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts, Journal of Immunology, 134, 3504-3515.
58. Vogelstein, B. and Kinzler, K. W. (1992). p53 function and dysfunction, Cell, 70, 523-526.
59. Harris, C. C. and Hollstein, M. (1993). Clinical implications of the p53 tumor-suppressor gene, New England Journal of Medicine, 329, 1318-1327.
60. Miyashita, T. and Reed, J. C. (1993). Bcl-2 oncoprotein blocks chemotheraphy-induced apoptosis in a human leukemia cell line, Blood, 81, 151-157.